Carlos Cordero

Dr. Carlos Cordero


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2025 in Toxins
Verified
Journal Article
Open access
CCCarlos Cordero
Carlos Cordero
Irene De-TorresIrene De-Torres
Irene De-Torres
FJFormigo-Couceiro Jacobo
Formigo-Couceiro Jacobo
LGLuis Guirao
Luis Guirao
MRMª Dolores Romero-Torres
Mª Dolores Romero-Torres
AMAntonio Mena-Rodriguez
Antonio Mena-Rodriguez
The study aimed to identify expert opinions and obtain recommendations on the management of post-stroke hemiplegic shoulder pain (HSP) and treatment with botulinum toxin A (BoNT-A). A multicenter Delphi study was conducted using an online survey designed by a committee of experts with at least 10 years of experience in post-stroke HSP management with BoNT-A in Spain. Forty-seven panelists (specialists with at least 5 years of experience in post-stroke HSP management with BoNT-A) rated their level of agreement in two rounds based on acceptance by ≥66.7% of them. In round 1, 245 statements on three dimensions were evaluated (diagnosis, treatment, and follow-up of the HSP patients treated with BoNT-A). A total of 159 statements (70.9%) were finally accepted after round 2. Experts recommended BoNT-A as soon as spasticity affects daily activities. They considered ultrasound as the preferred guided technique. Experts recommended regular assessments using validated scales and patient-reported outcomes to evaluate treatment goals and safety. In case of lack of response, experts suggested increasing the dose or number of treated muscles or considering alternative treatments. These consensus-based recommendations offer clinicians an approach to the management of post-stroke HSP with BoNT-A, supporting informed decision making.

8 September 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
CCCarlos Cordero
Carlos Cordero
JSJudith Sánchez‐Raya
Judith Sánchez‐Raya
TRTamara L. Rodríguez‐Araya
Tamara L. Rodríguez‐Araya
MLMaría Dolores López‐Alarcón
María Dolores López‐Alarcón
ETEva Trillo‐Calvo
Eva Trillo‐Calvo
MPMaria Pérez‐Páramo
Maria Pérez‐Páramo
Introduction: Low back pain (LBP) is one of the most prevalent chronic pain conditions that affects nearly 50% of the population. Its complex pathophysiology may involve both nociceptive and neuropathic mechanisms and is often resistant to standard treatment. Pregabalin has emerged as a potential alternative owing to its mechanism of action, the inhibition of excitatory neurotransmitter release. This meta-analysis aimed to evaluate the efficacy and safety of pregabalin in managing LBP.Methods: A systematic review of three major databases was conducted following the PRISMA guidelines. Studies were included if they were comparative studies of pregabalin with placebo or other pain medications, focusing on adult patients with LBP. Data were extracted on efficacy outcomes including pain reduction, anxiety, depression, quality of life, quality of sleep, disability, and adverse events. Statistical analysis was performed using Review Manager 5.4.1.Results: A total of 18 studies (n = 5,000) were included. Pregabalin demonstrated significant pain reduction at 4 weeks (Standardized Mean Difference (SMD) = −0.64, 95% Confidence Interval (CI) = −1.09 to −0.20), 6 weeks (SMD = −0.72, 95% CI = −1.15 to −0.29), and 8 weeks (SMD = −0.50, 95% CI = −0.71 to −0.29) compared to control group. Pregabalin also showed a significant greater improvement in anxiety (Mean Difference (MD) = −1.38, 95% CI = −1.74 to −1.02, p < 0.00001), depression (MD = −1.40, 95% CI = −1.71 to −1.08, p < 0.00001), quality of life (SMD = 0.22, 95% CI = 0.07 to 0.37, p = 0.003) and sleep quality (SMD = −0.61, 95% CI = −0.87 to −0.36, p < 0.00001). There were no significant differences regarding disability and adverse events.Conclusion: Pregabalin in the treatment of neuropathic LBP demonstrated significant improvements in pain relief, associated symptoms of anxiety and depression, and enhancements in quality of life and sleep quality. In addition, it exhibits a favorable safety profile. Nevertheless, these findings should be interpreted with caution due to the limited quality of the evidence and the inadequate reporting of pain etiology in several included studies.